The upgrade from Neutral to Overweight by Piper Sandler indicates a positive outlook for Deciphera Pharmaceuticals. The raised price target from $18 to $23 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and potentially a rise in the stock price in the short term.